MA
VRTX icon

MJP Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

MJP Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-466
Closed -$226K – 246
2025
Q1 		$226K Buy
+466
New +$217K 0.04% 198
2024
Q4 		– Sell
-520
Closed -$242K – 244
2024
Q3 		$242K Sell
520
-108
-17% -$51.9K 0.05% 180
2024
Q2 		$294K Buy
628
+85
+16% +$36.9K 0.06% 172
2024
Q1 		$227K Buy
+543
New +$230K 0.05% 209

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MJP Associates's VRTX Position: Q2 2025 in Review

MJP Associates sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 466 shares — an estimated $226K sold.

MJP Associates first reported a position in VRTX in Q1 2024 and held it in 4 quarters. The position peaked at $294K in Q2 2024. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • MJP Associates reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • MJP Associates sold 466 Vertex Pharmaceuticals shares in Q2 2025, an estimated $226K.
  • MJP Associates first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • MJP Associates's Vertex Pharmaceuticals position peaked at $294K in Q2 2024.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on MJP Associates's 13F filing for Q2 2025, filed 8 Aug 2025.